Good evening :)
$
₹
Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

SNOA

NASDAQ
Asset Logo

Sonoma Pharmaceuticals Inc

SNOA

NASDAQ
$1.081.49% (+0.01)
$
₹
$1.081.49% (+0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Micro Cap

With a market cap of $5.3M the stock is ranked 5908

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.82
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.22
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.08
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-10.33%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

+1021.5%

Earnings Growth

+57.58%

Rev. Growth

+22.44%

See Detailed Forecast

Company Profile

Company Profile

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
45.74
45.74
1Y Return
47.62%
47.62%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.93
41.93
1Y Return
47.33%
47.33%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
151.87
151.87
1Y Return
74.12%
74.12%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
31.48
31.48
1Y Return
29.02%
29.02%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.73
26.73
1Y Return
14.37%
14.37%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 1021.50% growth, versus a trailing 3-year CAGR of -31.98%.

2026
Current$1.07Baseline
Analyst Target - 1 year
Target$12+1021.5%

All values in $

202220232024202520262027$6.88$12.80$18.72Target+1021.5%
2026
Current$1.07Baseline
Analyst Target - 1 year
Target$12+1021.5%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 22.44% growth, versus a trailing 3-year CAGR of 13.74%.

2026
Current$19.52Baseline
Forecast for Mar 2027
High$23.91+22.44%
Average$23.91+22.44%
Low$23.91+22.44%

All values in $ Million

20222023202420252026202712.6213.2712.7314.2819.52Low+22.44%Average+22.44%High+22.44%
2026
Current$19.52Baseline
Forecast for Mar 2027
High$23.91+22.44%
Average$23.91+22.44%
Low$23.91+22.44%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2026
Current$-1.32Baseline
Forecast for Mar 2027
High$-0.56+57.58%
Average$-0.56+57.58%
Low$-0.56+57.58%

All values in $

20232024202520262027-2.42-7.75-3.1-1.32Low+57.58%Average+57.58%High+57.58%
2026
Current$-1.32Baseline
Forecast for Mar 2027
High$-0.56+57.58%
Average$-0.56+57.58%
Low$-0.56+57.58%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

5.6
-0.5
4.3
-0.8
5.5
-0.5
6.4
-0.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue3.433.393.573.563.754.015.604.345.566.40
Net Income-1.06-1.14-0.61-0.92-0.77-1.24-0.53-0.81-0.58-0.33
Net Profit Margin-31.02%-33.70%-17.04%-26.03%-20.67%-30.90%-9.52%-18.83%-10.44%-5.15%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Sonoma Pharmaceuticals Inc -0.821.08
Eli Lilly and Company45.7431.171.32
Johnson & Johnson41.937.852.99
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SNOA with any stock or ETF
Compare SNOA with any stock or ETF
Comparing from
SNOA
LLY
JNJ
Loading...

Frequently asked questions

  1. Sonoma Pharmaceuticals Inc (SNOA) share price today is $1.08 as of November 6, 2026 at 8:28 PM IST. The stock touched a day high of $1.11 and a day low of $1.08.

  2. Sonoma Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol SNOA.

  3. Sonoma Pharmaceuticals Inc's market capitalization is $5.31M as of November 6, 2026 at 8:28 PM IST.

  4. Sonoma Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Sonoma Pharmaceuticals Inc's price-to-book (P/B) ratio is 0.82 as of November 6, 2026.

  6. Yes, You can buy Sonoma Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Sonoma Pharmaceuticals Inc shares in three steps: 1. Search Sonoma Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Sonoma Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Sonoma Pharmaceuticals Inc (SNOA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 9.2081 shares at the current price of $1.08.

Loading...